` VYNE (Vyne Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

VYNE
vs
S&P 500

Over the past 12 months, VYNE has underperformed S&P 500, delivering a return of -84% compared to the S&P 500's +18% growth.

Stocks Performance
VYNE vs S&P 500

Loading
VYNE
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
VYNE vs S&P 500

Loading
VYNE
S&P 500
Difference
www.alphaspread.com

Performance By Year
VYNE vs S&P 500

Loading
VYNE
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Vyne Therapeutics Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Vyne Therapeutics Inc
Glance View

Market Cap
17.7m USD
Industry
Pharmaceuticals

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 28 full-time employees. The company went IPO on 2018-01-25. The firm is engaged in developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s proprietary pipeline FMX114, which is a potential treatment of mild-to-moderate atopic dermatitis in patients 12 years of age and older, and access to a library of bromodomain and extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.

VYNE Intrinsic Value
0.041 USD
Overvaluation 93%
Intrinsic Value
Price
Back to Top